Last updated on September 2018
Phase 1 Study of E7090 in Subjects With Solid Tumor
Brief description of study
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts:
- Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and
- Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.
Clinical Study Identifier: NCT02275910
Start Over
Connect »